Juva Life begins construction on Redwood City retail store, on track to open in early 2023, The Canadian Business Journal

VANCOUVER, British Columbia, November 8, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or “Company”) ), a life sciences company with both pharmaceutical research and development and consumer operations in cannabis production and distribution, announced today that it has begun construction on its next retail location in Redwood City, Calif. . The cannabis retail store is scheduled to open in the first quarter of 2023 at 2301 Broadway Street in downtown Redwood City, California.

“Starting construction of our Redwood City retail store is an exciting process and we expect it to open in early 2023. Doug Chloupek, CEO and Founder of Juva Life, said: “Juva was the first cannabis delivery company to operate in Redwood City and the first retail We also look forward to becoming a store, and look forward to further strengthening our presence and deepening our connection with our customers in the region.”

Redwood City, California has a retail cannabis program developed with community support after the state legalized the sale of adult cannabis in 2018. Approval within Redwood City allows for over-the-counter retail cannabis businesses in commercial and mixed-use zones. The process included a merit-based application to ensure that high-quality retail cannabis operators were thoroughly vetted and fully qualified before receiving a permit. Juva Retail RWC Inc. was the highest scoring applicant overall, earning a total of 1,876 points in Phase III. Combined with his 1,196 points in our Phase II score, this equates to 3,072 points for a total score of 96%.

Additionally, Juva Life continues its dual approach to business, with the other side of the business consisting of pharmaceutical research and rigorous cannabis science, unlocking the secrets behind the anecdotal benefits of the cannabis plant. increase. Juva continues its discovery efforts to identify new compounds and advance JUVA-041 through industry-standard preclinical inflammation models and preclinical studies that enabled his IND submission. Beyond clinical research programs, Juva recently relaunched his WIRB-approved JuLi Registry study, with the goal of cultivating one of the largest datasets on the medical uses of cannabis use to date. .

On behalf of the Board of Directors,

-Doug Klopek-

Doug Klopeck, CEO and Founder

Juba Life Co., Ltd.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life uses cutting-edge science to discover, develop and commercialize safe and effective health and medicines for both the cannabis consumer segment and the non-cannabinoid-based medical industry. The company is on track to execute his 2018 roadmap, initially by standardizing cultivation, extraction and formulation to deliver reproducible benefits to consumers. Juva has built on these natural product process chemistry skills and now incorporates discovery pharmacology. The Company will leverage the revenues generated from its retail operations to invest in Juva-019 and Juva-041 consumer and clinical development efforts, as well as other potentially valuable pharmaceuticals with significant consumer product and pharmaceutical applications. Promotes non-cannabinoid bioactive substances. Juva is committed to aligning the cannabis market with the next generation of investment grade business models in the space. For more information, see: https://juvalife.com/.

For more information, please contact:

Juba Life Investor Information

phone number: +1 833-333-5882 (Juba)

Email: [email protected]

Investor Relations:
Kyle Porter
858.221.8001
[email protected]

Corporate contact:
1.833.333.JUVA (5882)

forward-looking statements

To the extent that this news release is not historical fact, this news release contains statements and information that may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections and statements regarding future plans, objectives or economic performance or the assumptions underlying any of the foregoing. In some cases, forward-looking statements are “may,” “would,” “could,” “will,” “likely,” “exclude,” and “expect.” can be identified by terms such as , “believe” and “intend”. , “plans”, “forecasts”, “plans”, “estimates”, “outlooks” or other similar expressions relating to the negative of these or matters that are not historical facts. Examples of such statements include, but are not limited to, statements regarding our purpose and business plans. Product development, commercialization strategies and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and the Company’s actual results, performance or performance may differ materially from future results, performance or performance expressed or implied by forward-looking information. It includes other factors that can cause different. risks associated with our future business plans; The risk that we may not be able to secure key personnel; As with all other risks described in our management’s discussion and analysis under the heading “Risks and Uncertainties” for the year ended December 31, 2020, we The risk of not being able to secure funding on terms or the risk of not being able to raise funding at all. Accordingly, readers should not place undue reliance on such forward-looking information. In addition, forward-looking information speaks only as of the date such statements are made. New factors emerge from time to time and it is not possible for our management to predict all such factors, and we may not be able to predict the impact of each such factor, or factor or combination of factors, on our business. It is impossible to assess in advance how much it will be affected. , actual results may differ materially from those contained in the forward-looking information. We do not use forward-looking information to reflect information or events after the date they were made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. shall not be obliged to update to

CSE does not take responsibility for the adequacy or accuracy of this release.

CBJ Newsmaker